Q3 snapshot: The IPO market shows fresh signs of improvement, but the biotech crunch continues to bite
The biotech IPO market crashed hard last year, but we’re seeing the window creak open in a steady upward trend in 2023 that bodes for better times — though it’s a long, long way from a boom.
Chris Dokomajilar at DealForma is back crunching the numbers, and we’ll start with signs that biotechs are brushing the dust off their S-1s and going back to the market in search of cash to grow their businesses.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.